Acamprosate Calcium
Phase 3Small molecule
Acamprosate Calcium is one of 84 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
220 competitors in Amyotrophic Lateral Sclerosis
#DrugCompanyPhaseTrials
1Tivicay
GSKPhase 3
Radicava
ShionogiPhase 3
Simdax
Orion Corporation, Orion PharmaPhase 3
Robitussin
PfizerPhase 3
Ultomiris
AstraZenecaPhase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Minocin
TTriax
Phase 3
Sodium Valproate
AstraZenecaPhase 3
BOTULINUM TOXIN TYPE B
EisaiPhase 3
Nolvadex
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Alcohol Dependence1 trial
Alcohol Use Disorder1 trial
Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder
Recruiting·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 4·NCT06269627·48 enrolled
Amyotrophic Lateral Sclerosis1 trial
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
Active, not recruiting·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT07204977·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Acamprosate Calcium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTechnische Universität Dresden